Sirnaomics Announces Interim Data from Phase I Clinical Trial of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors
Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma In Situ
Our Clinical Development Pipeline is focused on discovering and developing innovative drugs for indications
Our mission is to become a fully-integrated international biopharmaceutical company, leveraging our deep experience in RNA therapeutics and novel delivery platform technologies to rapidly discover and develop innovative drugs for indications with significant unmet medical needs in areas such as cancers, skin conditions, fibrosis-related diseases, antiviral and cardiometabolic diseases, and medical aesthetics.